NREP
NEW REPRESENTATIVE AT IB RECEIVED
17/11/2023
Voltar para busca
Dado oficial do USPTO
PANPHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
17/11/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
19/05/2014
Data de registro
21/07/2015
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/02/2022
Última transação
04/02/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
F-35133 LUITRE, FR
Examinador
SMITH, CYNTHIA RINALDI
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
PANPHARMA, Société anonyme
Representantes
WILLIAM C. WRIGHT EPSTEIN DRANGEL LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of allergiesdiseases related to the central nervous systemimmune system diseasesautoimmune diseasesinflammatory diseasesrheumatoid arthritisankylosing spondilitisobesitydiabetesdyslipemiabrain diseaseslocomotor disorders of the central nervous systembreak downmultiple sclerosisthrombosis and cancercardiovascular diseasesrespiratory system diseasesdigestive system diseaseshaematological system and skeletal system diseasespsychiatric disordersskin and subcutaneous tissue disordersrenal and urinary disordersbronchial disordersasthmasinusitisflu-like statesfeverish achesgrowth and mineralization disordersveinolimphatic insufficiency and disorderscapillary fragility disordersacute haemorroidal episodesinfectious conditionstravel sicknesshealing of wounds and burnssleep disordersnausea and vomitingconstipationdiarrheasintestinal disordersnervousnessstresshysteriafearsanxiety and temporary tirednessneurotonic conditionsgoutcoldrhinitiscoughinfluenzasrhinopharyngitissore throatstracheitislaryngitis and bacterial and non-bacterial anginashoarsenesskickslumps and contusionseczemacholesteroldegenerationscutaneous and mucuous disordersphysical and psychic astheniamenopausemenstruation-related disordersallergic disordersgynaecological diseasesrheumatic diseasesurological diseasesgastro-enterological diseasesophtalmological diseasesdermatological diseasesgenital diseasesendocrine diseasesintestinal diseasesblood-related diseasesdiseases related to internal medicinecirculatory disordersmuscular disordersnephropathypulmonary embolismhypertensionatherothrombosisarrythmiahearing failureepilepsyschizophrenianeurotic and psychosomatic disordershyperplasiaprostatetoxoplasmosismalariamalignant and benign tumorshypercalcemiahyperuremiatuberculosiswhooping coughdiphtheriapoliomyelitisrabiesallergic reactionsmetabolic disordercontrol of allergic reactions or metabolic disorders; pharmaceutical preparations for smoking cessationpharmaceutical sedativestranquilizersdepuratives for the body; vitaminmineral supplements and vaccines for use on domestic animals and livestock for veterinary purposes; dietetic foodscrackerscakessoupmeal replacement barsfruit and vegetable granules adapted for medical use; pesticidespreparations for destroying vermin within the province of the pharmaceutical sector
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
13/11/2022
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
14/10/2022
INPC
INVALIDATION PROCESSED
14/10/2022
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
04/10/2022
C71T
CANCELLED SECTION 71
04/02/2022
RNWL
INTERNATIONAL REGISTRATION RENEWED
02/12/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
27/02/2021
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
21/07/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/02/2016
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
10/12/2015
XXCR
GENERIC MADRID TRANSACTION CREATED
10/12/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/10/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
21/07/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/05/2015
PUBO
PUBLISHED FOR OPPOSITION
05/05/2015
GPNX
NOTIFICATION PROCESSED BY IB
02/05/2015
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
15/04/2015
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
15/04/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/04/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
28/03/2015
ALIE
ASSIGNED TO LIE
23/03/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/03/2015
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/03/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/03/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/03/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/03/2015
RFNT
REFUSAL PROCESSED BY IB
25/09/2014
MAFR
APPLICATION FILING RECEIPT MAILED
06/09/2014
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/09/2014
RFRR
REFUSAL PROCESSED BY MPU
05/09/2014
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/09/2014
CNRT
NON-FINAL ACTION WRITTEN
04/09/2014
DOCK
ASSIGNED TO EXAMINER
03/09/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/09/2014
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
28/08/2014
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PANPHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.